ProteqFlu
Equine influenza vaccine (live recombinant)
Table of contents
Overview
This is a summary of the European Public Assessment Report. Its purpose is to explain how the assessment done by the Committee for Medicinal Products for Veterinary Use (CVMP) on the basis of the documentation provided, led to the recommendations on the conditions of use.
This summary cannot replace a face-to-face discussion with your veterinarian. If you need more information about your animal’s medical condition or treatment, contact your veterinarian. If you want more information on the basis of the CVMP recommendations, read the scientific discussion (also part of the EPAR).
Authorisation details
Product details | |
---|---|
Name |
ProteqFlu
|
Agency product number |
EMEA/V/C/000073
|
Active substance |
Vcp 2242 virus / Vcp1529 virus / Vcp1533 virus / vCP3011 virus
|
International non-proprietary name (INN) or common name |
Equine influenza vaccine (live recombinant)
|
Species |
Horses
|
Anatomical therapeutic chemical veterinary (ATCvet) codes |
QI05AD02
|
Publication details | |
---|---|
Marketing-authorisation holder |
Boehringer Ingelheim Vetmedica GmbH
|
Revision |
14
|
Date of issue of marketing authorisation valid throughout the European Union |
06/03/2003
|
Contact address |
Product information
29/07/2020 ProteqFlu - EMEA/V/C/000073 - IG/1264
Contents
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
Pharmacotherapeutic group
-
Immunologicals
-
Live viral vaccines equine influenza virus
Therapeutic indication
Active immunisation of horses of four months of age or older against equine influenza to reduce clinical signs and virus excretion after infection.